Charles Schwab
TSHA icon

Charles Schwab’s Taysha Gene Therapies TSHA Stock Holding History

Charles Schwab’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
2,200,695
+392,096
+22% +$2.32M ﹤0.01% 1966
2026
Q1 		$8.08M Sell
1,808,599
-94,379
-5% -$439K ﹤0.01% 2203
2025
Q4 		$10.5M Buy
1,902,978
+56,468
+3% +$274K ﹤0.01% 2121
2025
Q3 		$6.04M Buy
1,846,510
+1,354,801
+276% +$3.84M ﹤0.01% 2348
2025
Q2 		$1.14M Sell
491,709
-55,419
-10% -$120K ﹤0.01% 2861
2025
Q1 		$761K Buy
547,128
+72,871
+15% +$122K ﹤0.01% 2937
2024
Q4 		$820K Buy
474,257
+11,390
+2% +$23.6K ﹤0.01% 2974
2024
Q3 		$930K Buy
462,867
+33,123
+8% +$72.7K ﹤0.01% 2938
2024
Q2 		$963K Buy
429,744
+378,282
+735% +$1.1M ﹤0.01% 2950
2024
Q1 		$148K Buy
51,462
+35,322
+219% +$73.6K ﹤0.01% 3269
2023
Q4 		$28.6K Hold
16,140
– – ﹤0.01% 3454
2023
Q3 		$51K Hold
16,140
– – ﹤0.01% 3407
2023
Q2 		$10.7K Hold
16,140
– – ﹤0.01% 3595
2023
Q1 		$12.9K Hold
16,140
– – ﹤0.01% 3532
2022
Q4 		$36.5K Hold
16,140
– – ﹤0.01% 3422
2022
Q3 		$32K Sell
16,140
-74,571
-82% -$271K ﹤0.01% 3417
2022
Q2 		$338K Sell
90,711
-74,634
-45% -$296K ﹤0.01% 3176
2022
Q1 		$1.08M Buy
165,345
+2,785
+2% +$20.8K ﹤0.01% 2820
2021
Q4 		$1.89M Buy
162,560
+4,153
+3% +$62.6K ﹤0.01% 2719
2021
Q3 		$2.95M Buy
158,407
+71,377
+82% +$1.36M ﹤0.01% 2609
2021
Q2 		$1.85M Buy
87,030
+28,787
+49% +$664K ﹤0.01% 2745
2021
Q1 		$1.18M Buy
58,243
+6,011
+12% +$163K ﹤0.01% 2799
2020
Q4 		$1.39M Buy
+52,232
New +$1.13M ﹤0.01% 2686

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Charles Schwab's TSHA Position: Q2 2026 in Review

Charles Schwab increased its Taysha Gene Therapies (TSHA) stake by 22% in Q2 2026, buying an estimated $2.32M and bringing the position to 2,200,695 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Charles Schwab first reported a position in TSHA in Q4 2020 and has held it in 23 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Charles Schwab held 2,200,695 shares of Taysha Gene Therapies worth $15M as of Q2 2026.
  • Charles Schwab bought 392,096 Taysha Gene Therapies shares in Q2 2026, an estimated $2.32M.
  • Taysha Gene Therapies made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1966 holding.
  • Charles Schwab first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 23 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.